Chemotherapy Resistance and Sensitivity Testing in Lung Tumors

The chemosensitivity assay will be performed on tissue obtained during the diagnostic fine
needle aspiration, core biopsy, or excisional biopsy of the lung lesion. Cancer cells (Bulk
of tumor) and Cancer Stem Cells (CSCs) will be isolated and expanded in the laboratory.

The drug screening assay will be used to evaluate the response of the CSCs and of the cancer
cells to the various chemotherapy regimens.

Inclusion Criteria:

- suspected or confirmed diagnosis of lung cancer

- undergoing a fine needle aspiration, core biopsy, or excisional biopsy for
diagnosis.

- Chemotherapy must be clinically indicated for treatment of the patient's qualifying
disease

- Patient must be at least 18 years of age

- Patient must have signed an IRB approved informed consent form for the data
collection study prior to entry of data into the enrollment form in the database.

Exclusion Criteria:

- Patient pathology shows benign pathology for sample submitted

- Patient is not indicated to receive chemotherapy for their disease